These CD8+ CTLs are mainly activated by dendritic cells (DCs) expressing both tumor-derived epitope peptide(s) presented by class I MHC molecules and by co-stimulatory molecules, such as CD40, CD80, and CD86. This evidence concerns the gene CD8A and neoplasm.